Stay updated on Pembrolizumab for High-Grade Neuroendocrine Carcinomas Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for High-Grade Neuroendocrine Carcinomas Clinical Trial page.

Latest updates to the Pembrolizumab for High-Grade Neuroendocrine Carcinomas Clinical Trial page
- ChecktodayChange DetectedThe page received a minor version update (revision to a newer build). This appears to be software maintenance with no visible changes to the study details, eligibility criteria, or results.SummaryDifference0.1%

- Check7 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page’s footer version/release label was updated from v3.5.2 to v3.5.3, indicating a ClinicalTrials.gov site revision rather than any modification to the trial record.SummaryDifference0.1%

- Check29 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check58 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check65 days agoChange DetectedPage revision updated from v3.4.2 to v3.4.3. There are no apparent changes to the study content or results.SummaryDifference0.1%

- Check94 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2 on the page. This appears to be a minor site revision.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab for High-Grade Neuroendocrine Carcinomas Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for High-Grade Neuroendocrine Carcinomas Clinical Trial page.